The Leukaemia Foundation is today welcoming the news of the unrestricted benefits listing announcement of the blood cancer drug Pegasys® (pegylated interferon alfa-2a) for Australians living with Myeloproliferative neoplasms (MPNs).
The support follows the $250 million announcement today by Health Minister Greg Hunt to subsidise four life-changing cancer medicines, including Pegasys® and also upcoming discounted access to the drug IMBRUVICA® (ibrutinib) to treat patients living with relapsed or refractory mantle cell lymphoma, another type of blood cancer.
Today’s funding announcement means patients who currently pay $134,000 for the drug Imbruvica would also now have discounted access from August.
The Leukaemia Foundation’s priority is to ensure all Australians living with a blood cancer have access to the best therapies and treatments available.
The Leukaemia Foundation has, and will continue to fully support the unrestricted benefits listing of Pegasys® (pegylated interferon alfa-2a) for MPNs patients and looks forward to the upcoming discounted access to Imbruvica.
The Leukaemia Foundation is the only national charity dedicated to helping Australians affected by a blood cancer such as leukaemia, lymphoma, myeloma and related blood disorders.
